Ocular Therapeutix Cash Flow Statement
NASDAQ: OCULHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.54+0.03 (+0.40%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ocular Therapeutix free cash flow
In fiscal 2025, Ocular Therapeutix generated -$204.9 million of operating cash flow and spent $12.0 million on capital expenditures. That left free cash flow of -$216.9 million, a free-cash-flow margin of -417.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Ocular Therapeutix cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -265.94M | -193.51M | -80.74M | -71.04M | -6.55M | -155.64M | -86.37M | 59.98M | 63.39M | -44.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | -244.01% | -5.38% | — | — |
| Depreciation & Amortization | 4.32M | 3.79M | 2.98M | 2.11M | 2.42M | 2.77M | 2.53M | 2.29M | 1.63M | 881.00K |
| Stock-Based Compensation | 43.18M | 33.11M | 17.82M | 16.96M | 14.98M | 7.53M | 8.76M | 7.48M | 7.32M | 5.96M |
| Change in Working Capital | 8.05M | -9.55M | -7.17M | 1.79M | -2.52M | 1.49M | -1.76M | 585.00K | 3.55M | 2.08M |
| Operating Cash Flow | -204.88M | -134.68M | -70.23M | -59.60M | -65.55M | -53.55M | -77.58M | -49.23M | -50.47M | -34.00M |
| Capital Expenditures | -12.01M | -1.29M | -6.09M | -3.71M | -1.19M | -841.00K | -2.24M | -1.89M | -8.25M | -1.92M |
| Investing Cash Flow | -11.88M | -1.29M | -6.09M | -3.71M | -1.19M | -841.00K | -2.24M | -1.89M | 26.95M | 37.07M |
| Debt Issued | — | — | 82.47M | — | — | — | — | — | — | — |
| Debt Repaid | — | — | -26.13M | — | — | — | — | — | — | — |
| Financing Cash Flow | 561.72M | 332.11M | 169.83M | 1.45M | 2.85M | 228.01M | 75.34M | 68.64M | 32.01M | 585.00K |
| Net Change in Cash | 344.96M | 196.15M | 93.51M | -61.86M | -63.89M | 173.62M | -4.47M | 17.52M | 8.49M | 3.65M |
| Free Cash Flow | -216.89M | -135.97M | -76.32M | -63.32M | -66.74M | -54.40M | -79.82M | -51.12M | -58.73M | -35.92M |
This table shows 10 annual periods of Ocular Therapeutix's cash flow statement, from FY 2025 back to FY 2016, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow OCUL's reporting calendar. What is a cash flow statement?